Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Research (ARWR) today and set a price target of $32. The company’s shares closed yesterday at $27.24.
According to TipRanks.com, Nakae is ranked 0 out of 5 stars with an average return of -12.4% and a 32.1% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Emergent Biosolutions.
Arrowhead Research has an analyst consensus of Moderate Buy, with a price target consensus of $29.33.
See today’s analyst top recommended stocks >>
Arrowhead Research’s market cap is currently $2.58B and has a P/E ratio of 400.59. The company has a Price to Book ratio of 12.82.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is neutral on the stock. Most recently, in June 2019, Kenneth Allen Myszkowski, the CFO of ARWR bought 35,000 shares for a total of $172,800.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
